Drug Trial Radar · NCT03830671
The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB
Last checked: Nov 19, 2026Latest source record: Oct 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
515
Actual
Start
Mar 8, 2019
Primary completion
Jun 8, 2022
Study completion Jun 8, 2022
Sponsor
- Lead sponsor
- Beijing Chest HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
WHO has recommended that multidrug-resistant tuberculosis (MDR-TB, defined as resistance to at least isoniazid (H) and rifampicin (R) be addressed as a public health crisis and enhance capacity to deliver effective treatment and care. According to the 2018 WHO TB Report, the overall treatment success rate of MDR-TB is 55% while much lower in China at just only 41% with the 24-month regimen. In order to further verify the safety and efficiency of optimizing shorter 18-month regimen containing 6 anti-TB drugs with MDR-TB patients,500 more patients will be enrolled and observed.
Conditions
- Multi-drug Resistant Tuberculosis
Interventions
18-month regimen containing 6 anti-TB drugsDrug
Investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The abbreviation of the name of each drug in the regimen is explained as follows: PZA-pyrazinamide,Am-Amikacin,Mfx-moxifloxacin)and the total duration of the regimen is 18 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- the treatment success rateTime frame: at the end of treatment completion of all enrolled patients,an average of 18 months after the last patient enrolled
- death rateTime frame: at the end of treatment completion of all enrolled patients, an average of 18 months after the last patient enrolled
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chest Hospital
Beijing, China
The 8th Medical Center of Chinese Pla General Hospital
Beijing, China
Changchun Infectious Disease Hospital
Changchun, China
Hunan Institute For Tuberculosis Control
Changsha, China
Public Health Clinical Center of Chengdu
Chengdu, China
Shenzhen Third Peple's Hospital
Guangzhou, China
Guangzhou Chest Hospital
Guanzhou, China
The Affiliated Hospital of Guizhou Medical University
Guiyang, China
Infectious Disease Prevention Hospital in Heilongjiang Province
Harbin, China
Anhui Chest Hospital
Hefei, China
The Fourth People's Hospital of Inner Mongolia Autonomous region
Hohhot, China
Shandong Provincial Chest Hospital
Jinan, China
Shanghai Pulmonary Hospital
Shanghai, China
Shenyang Chest Hospital
Shenyang, China
Tianjin Haihe Hospital
Tianjin, China
Chest of Hospital of Xinjiang Uygur Autonomous Region of the PRC
Ürümqi, China
The Tuberculosis Prevention and Treatment Hospital of Shanxi Province
Xi'an, China
Xi'an Chest Hospital
Xi'an, China
The Fourth People's Hospital of Ningxia Autonomous Region
Yinchuan, China
The Infectious Disease Hospital of Wangkai Zaozhuang
Zaozhuang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.